Cellid, Co., Ltd.
KOE: 299660.KQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Yuil Kang Chang
- Employees
- 64
- Headquarters
- Seoul, South Korea
- IPO year
- 2019
- Market cap
- ₩101.8B
- Website
- http://www.cellid.co.kr
Loading 299660…
Loading profile data…Frequently asked questions about 299660
What does Cellid, Co., Ltd. (299660.KQ) do?
Cellid, Inc. develops immunothetherapeutic vaccines for cancer and/or infectious diseases therapies. It is developing BVAC-C for cervical, head and neck, anal, and genital cancer with human papilloma virus antigen; BVAC-B for gastric, ovarian, lung, and pancreatic cancer with HER-2/neu antigen; and BVAC-P for prostate, urinary tract, and brain c...
Where does 299660.KQ trade?
Cellid, Co., Ltd. (299660.KQ) trades on the KOSDAQ.
What sector is 299660.KQ in?
Cellid, Co., Ltd. (299660.KQ) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Cellid, Co., Ltd.?
Yuil Kang Chang is the chief executive officer of Cellid, Co., Ltd. (299660.KQ).
Where is Cellid, Co., Ltd. headquartered?
Cellid, Co., Ltd. is headquartered in South Korea.
Does 299660.KQ pay a dividend?
Cellid, Co., Ltd. (299660.KQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 299660.KQ go public?
Cellid, Co., Ltd. (299660.KQ) completed its initial public offering in 2019.